Targets › CTRL
1 program from 1 company in 1 trial: 1 Phase 2; Gastroenterology.
Open in Phaseline: the race on CTRL, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Healthgen Biotechnology | Recombinant Human Chymotrypsin (OsrhCT) Serine protease; mucolytic enzyme to improve gastric mucosa visualization | CTRL | Phase 2 | Gastric Mucosal Lesion | – |
Gastric Mucosal Lesion (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.